{"url_path":"/sec/eltx/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001104659-26-080058-index.html","accession_number":"0001104659-26-080058","cik":"0001601485","ticker":"ELTX","issuer_name":"Elicio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001104659-26-080058-index.html","primary_entity_key":"0001601485","primary_entity_name":"Elicio Therapeutics, Inc."},"word_count":202,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits**\n\n** **\n\n**(d) Exhibits**\n\n** **\n\n**Exhibit\nNo.**\n \n**Description**\n\n \n \n \n\n[5.1](tm2619637d1_ex5-1.htm)\n \n[Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.](tm2619637d1_ex5-1.htm)\n\n \n \n \n\n[10.1](tm2619637d1_ex10-1.htm)\n \n[Form of Securities Purchase Agreement, dated as of July 1, 2026, by and among Elicio Therapeutics, Inc. and the purchasers party thereto.](tm2619637d1_ex10-1.htm)\n\n \n \n \n\n[10.2+ ](tm2619637d1_ex10-2.htm)\n \n[Placement Agency Agreement, dated as of July 1, 2026, by and between Elicio Therapeutics, Inc. and Titan Partners Group LLC, a division of American Capital Partners, LLC.](tm2619637d1_ex10-2.htm)\n\n \n \n \n\n[23.1](tm2619637d1_ex5-1.htm)\n \n[Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).](tm2619637d1_ex5-1.htm)\n\n \n \n \n\n[99.1](tm2619637d1_ex99-1.htm)\n \n[Pricing Press Release, dated July 1, 2026.](tm2619637d1_ex99-1.htm)\n\n \n \n \n\n104\n \n\nCover Page Interactive Data File (formatted as Inline XBRL and contained\nin Exhibit 101)\n\n \n\n \n\n** **+\n    Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes\nto furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission. \n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \n**Elicio Therapeutics, Inc.**\n\n \n \n \n\n \nBy:\n/s/ ROBERT CONNELLY\n\nDate: July 2, 2026\n \n\nRobert Connelly\n\n*President and Chief Executive Officer*\n\n*(Principal Executive Officer)*"}